Early and maintained comparative effectiveness of 5 different classes of advanced therapies in a large multinational cohort of real-world PsA patients - report from EULAR2024

Professor Dennis McGonagle explains the results of an EULAR 2024 late breaking abstract, the PRO-SPIRIT study, early (3-month) and maintained (12-month) comparative effectiveness of 5 different classes of advanced therapies in a large multinational cohort of real-world PsA patients. Video: https://medicaldigest.org/scientific-contents/interview:early-and-maintained-comparative-effectiveness-5-different-classes-advanced-therapies-large-multinational-cohort-real-world-psa-patients